Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire•30/10/2026•08:00 ET
0
Key Highlights
- ➤$481.6 million cash and investments projected to fund operations into early 2029
- ➤UPSTREAM MG Phase 3 enrollment completed; topline results anticipated in 1H 2027
- ➤UPSTREAM oMG Phase 3 trial planned; first patient dosing anticipated in 1H 2027
- ➤Q3 R&D expenses rose to $34.5 million from $14.1 million year over year
- ➤TELIGAN IgAN trial showed eGFR decline of -0.6 versus -5.7 mL/min/1.73 m²/year placebo
Expert Statements
Jean-Paul Kress, M.D., Chairman and Chief Executive Officer of Vor Bio
“We ended the third quarter with UPSTREAM MG fully enrolled and three registrational clinical trials advancing across the MG spectrum and Sjögren’s disease”
Jean-Paul Kress, M.D., Chairman and Chief Executive Officer of Vor Bio
“The final two-year Phase 3 TELIGAN results in IgAN from China add another important layer to the clinical evidence for telitacicept, demonstrating durable preservation of kidney function and sustained proteinuria reduction through 104 weeks.”
Jean-Paul Kress, M.D., Chairman and Chief Executive Officer of Vor Bio
“Taken together with the growing experience across autoimmune diseases, these data continue to strengthen our view of what dual BAFF and APRIL inhibition may be able to achieve over time.”
Jean-Paul Kress, M.D., Chairman and Chief Executive Officer of Vor Bio
“As we approach 2027, our focus is on generating the evidence that can define the role of telitacicept and establish Vor as a leading company in immunology.”
Completed enrollment in Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis; topline results remain on track for 1H27
Expanded telitacicept franchise into ocular myasthenia gravis with Phase 3 registrational UPSTREAM oMG trial; first patient dosing anticipated in 1H27
Get started
Create a free account to read the full story.